DURHAM, N.C.--(BUSINESS WIRE)--Trimeris, Inc. (NASDAQ: TRMS) (“Trimeris” or the “Company”), a biopharmaceutical company engaged in the commercialization of therapeutic agents for the treatment of HIV, today announced that it has received a NASDAQ Staff determination letter dated January 5, 2010, notifying the Company that its common stock is subject to delisting due to the Company’s failure to hold its required annual meeting for fiscal year 2009.
